Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Filip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, Naijun Chen, Chen Wang, Vishvas Garg, Jasmina Kalabic, Filip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, Naijun Chen, Chen Wang, Vishvas Garg, Jasmina Kalabic

Abstract

Introduction: Patients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a proprietary patient support program (PSP, AbbVie Care®). The main objective of this study was to examine the effectiveness of ADA on RA treatment course over time in the context of PSP utilization.

Methods: PASSION was a 78-week post-marketing observational study of RA patients with an insufficient response to ≥1 DMARD newly initiating ADA in routine clinical care that was conducted in Europe, Israel, Mexico, Puerto Rico, and Australia. One prior biologic DMARD was allowed. The primary endpoint was percentage of patients achieving the minimal clinically important difference (MCID; improvement of ≥0.22 compared to baseline) in Health Assessment Questionnaire (HAQ) Disability Index (HAQ-DI) at week 78. Additionally, multiple clinical and patient-reported outcomes (PROs) were evaluated over time. Patients were categorized based on their participation in the PSP: ever (PSP users) vs. never (PSP non-users). Safety events were monitored throughout the study.

Results: Overall, 42.8% of PSP users achieved the MCID in HAQ-DI at week 78 (improvement of at least 0.22 compared to baseline). From 1025 enrolled, 48.7% of patients were PSP users while treated with ADA. The percentage of patients achieving MCID in the HAQ-DI was higher in PSP users vs. PSP non-users (48.1 vs. 37.8%) at week 78 (p < 0.001, NRI). Most of the studied clinical outcomes and PROs showed significant improvements (p < 0.05) from baseline to week 78 favoring PSP users over PSP non-users.

Conclusions: In patients with moderate-to-severe RA who initiated ADA, improvements in clinical, functional, and PROs were achieved in real-world settings with significantly greater improvements among PSP users in comparison with PSP non-users.

Funding: AbbVie.

Trial registration: ClinicalTrials.gov identifier, NCT01383421.

Keywords: Adalimumab; Patient support program; Rheumatoid arthritis.

Figures

Fig. 1
Fig. 1
Percentage of patients achieving MCID in HAQ-DI overtime
Fig. 2
Fig. 2
Changes from baseline in DAS28 (CRP) (a), SDAI (b), CDAI (c), HAQ-DI (d), and ACR response rates# (e) over time between PSP users and PSP non-users

References

    1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361. doi: 10.1038/nature01661.
    1. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2. Oxford: Oxford University Press; 2001.
    1. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15. doi: 10.1136/annrheumdis-2015-207524.
    1. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25:284–290. doi: 10.1007/s11606-010-1253-9.
    1. Sabaté E. World Health Organization: adherence to long-term therapies: evidence for action. Geneva, Switzerland. In: World Health Organization. 2003. Accessed 31 Aug 2016
    1. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337–351. doi: 10.1586/eci.12.23.
    1. Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adher. 2016;10:711–725.
    1. Stockl KM, Shin JS, Lew HC, et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm. 2010;16:593–604.
    1. Bruce B, Fries JF. The health assessment questionnaire (HAQ) Clin Exp Rheumatol. 2005;23:S14–S18.
    1. Stewart WF, Ricci JA, Leotta C, Chee E. Validation of the work and health interview. PharmacoEconomics. 2004;22:1127–1140. doi: 10.2165/00019053-200422170-00003.
    1. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol. 2003;30:2469–2475.
    1. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers Value in health. J Int Soc Pharmacoeconom Outcomes Res. 2005;8(Suppl 1):S9–S24.
    1. Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009;119:78–84. doi: 10.1111/j.1600-0447.2008.01279.x.
    1. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39:1005–1026. doi: 10.1111/j.1475-6773.2004.00269.x.
    1. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524. doi: 10.1136/annrheumdis-2011-201244.
    1. Burmester GR, Landewe R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:414–417. doi: 10.1136/annrheumdis-2016-209322.
    1. Burudpakdee C, Khan ZM, Gala S, Nanavaty M, Kaura S. Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis. Patient Pref Adher. 2015;9:435–448. doi: 10.2147/PPA.S77053.
    1. Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum. 1993;36:439–446. doi: 10.1002/art.1780360403.
    1. Barlow JH, Turner AP, Wright CC. Long-term outcomes of an arthritis self-management programme. Br J Rheumatol. 1998;37:1315–1319. doi: 10.1093/rheumatology/37.12.1315.
    1. Esselens G, Westhovens R, Verschueren P. Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskeletal Care. 2009;7:1–16. doi: 10.1002/msc.136.
    1. Rubin D, Skup M, Davis M, Johnson S. Impact of AbbVie’s patient support program on resource costs in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Managed Care Spec Pharm. 2015;21:S74–S75.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다